Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

To evaluate the effects of exenatide (EXE) on reproductive and metabolic function in overweight/obese (OW/OB) PCOS.

Why It Was Studied

Weight loss remains one of the most important arms in obese patients with polycystic ovary syndrome (PCOS).

Further studies are needed to identify the best treatment.

Who Took Part

The age groups tagged for this paper are teenagers, young adults and adults, women only.

Then all patients were treated with MET alone during the second 12 weeks.

How the Study Was Run

The design is described as randomized and open-label.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

Everyone knew when Exenatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

This is a 24-week open-label prospective, randomized, clinical study.

The researchers observed metabolic parameters at 0 and 12 weeks, and then tracked the rate of pregnancy during the second 12 weeks.

What Was Measured

The subject headings attached to it are Exenatide, Glucose Tolerance Test, Hypoglycemic Agents, Menstrual Cycle, Obesity, Overweight and Peptides.

The authors tagged it with the keywords insulin resistance, metformin, overweight/obese, polycystic ovary syndrome and pregnancy.

What This Means in Plain Language

The paper is a randomized and open-label study of Exenatide.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Clinical endocrinology), a journal based in England.

More context: the Exenatide compound page.